Immunotoxin-mediated depletion of Gag-specific CD8+ T cells undermines natural control of Simian immunodeficiency virus.

AIDS/HIV Adaptive immunity

Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
11 Jun 2024
Historique:
medline: 17 6 2024
pubmed: 17 6 2024
entrez: 17 6 2024
Statut: aheadofprint

Résumé

Antibody-mediated depletion studies have demonstrated that CD8+ T cells are required for effective immune control of SIV. However, this approach is confounded by several factors, including reactive CD4+ T cell proliferation, and further provides no specificity information. We circumvented these limitations by selectively depleting CD8+ T cells specific for the Gag epitope CTPYDINQM (CM9) via the administration of immunotoxin-conjugated tetrameric complexes of CM9/Mamu-A*01. Immunotoxin administration effectively depleted circulating but not tissuelocalized CM9-specific CD8+ T cells, akin to the bulk depletion pattern observed with antibodies directed against CD8. However, we found no evidence to indicate that circulating CM9-specific CD8+ T cells suppressed viral replication in Mamu-A*01+ rhesus macaques during acute or chronic progressive infection with a pathogenic strain of SIV. This observation extended to macaques with established infection during and after continuous antiretroviral therapy. In contrast, natural controller macaques experienced dramatic increases in plasma viremia after immunotoxin administration, highlighting the importance of CD8+ T cell-mediated immunity against CM9. Collectively, these data showed that CM9-specific CD8+ T cells were necessary but not sufficient for robust immune control of SIV in a nonhuman primate model and, more generally, validated an approach that could inform the design of next-generation vaccines against HIV-1.

Identifiants

pubmed: 38885329
pii: 174168
doi: 10.1172/jci.insight.174168
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Jennifer Simpson (J)

Barrier Immunity Section, National Institutes of Health, Bethesda, United States of America.

Carly E Starke (CE)

Barrier Immunity Section, National Institutes of Health, Bethesda, United States of America.

Alexandra M Ortiz (AM)

Barrier Immunity Section, National Institutes of Health, Bethesda, United States of America.

Amy Ransier (A)

Human Immunology Section, National Institutes of Health, Bethesda, United States of America.

Sam Darko (S)

Human Immunology Section, National Institutes of Health, Bethesda, United States of America.

Sian Llewellyn-Lacey (S)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.

Christine M Fennessey (CM)

AIDS and Cancer Virus Program, National Institutes of Health, Frederick, United States of America.

Brandon F Keele (BF)

AIDS and Cancer Virus Program, National Institutes of Health, Frederick, United States of America.

Daniel C Douek (DC)

Human Immunology Section, National Institutes of Health, Bethesda, United States of America.

David A Price (DA)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.

Jason M Brenchley (JM)

Barrier Immunity Section, National Institutes of Health, Bethesda, United States of America.

Classifications MeSH